Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with fluoropyrimidine and trastuzumab deruxtecan T-DXd compared to trastuzumab, chemotherapy, and pembrolizumab in participants with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 combined positive score CPS of 1 or higher. This Phase 3, randomized, open-label study also includes a separate group receiving rilvegostomig with trastuzumab and chemotherapy to understand the contribution of each treatment component. The study is being conducted globally across many sites in about 25 countries. Participants are assigned to one of three treatment groups Arm A receives rilvegostomig, fluoropyrimidine capecitabine or 5-fluorouracil, and trastuzumab deruxtecan Arm B receives pembrolizumab, trastuzumab, and chemotherapy 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin Arm C receives rilvegostomig, trastuzumab, and chemotherapy. Treatments are administered mainly through intravenous infusions every three weeks, with capecitabine taken orally twice daily. The study aims to assess the role of each treatment combination over time. During the study, participants will undergo regular assessments including tumor measurements, safety checks for adverse events, and blood tests to monitor drug levels and immune responses. Researchers will track progression-free survival and overall survival for up to six years, along with response rates and treatment side effects. The study includes ongoing monitoring for eating difficulties and side-effect impact. Participants will be followed closely throughout treatment and for years afterward to evaluate long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating baricitinib to see if it can preserve beta-cell function in children and adults newly diagnosed with type 1 diabetes. This Phase 3 randomized, double-blind, placebo-controlled study includes participants aged 1 to under 36 years who have been recently diagnosed with type 1 diabetes. The study aims to understand the impact of baricitinib on insulin-producing cells to potentially support better diabetes management. Participants will be randomly assigned to receive either oral baricitinib or a placebo. The treatment period lasts up to 52 weeks, during which participants will take their assigned study medication regularly. The study compares the effects of baricitinib against placebo to assess preservation of beta-cell function and related outcomes. Throughout the approximately 60-week participation, individuals will undergo multiple assessments including measuring C-peptide levels, hemoglobin A1c, insulin use, hypoglycemic events, growth parameters, and quality of life surveys. Safety and drug levels will also be monitored. These evaluations help researchers determine how the study drug affects diabetes control and participant health over time.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are evaluating the effectiveness of riliprubart compared to the usual treatment of intravenous immunoglobulin IVIg in adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP who are currently receiving maintenance IVIg therapy. This Phase 3 randomized study aims to understand how well riliprubart works in this group over a study duration of up to 109 weeks, including screening, treatment, and follow-up periods. Participants are randomly assigned to one of two groups one group receives riliprubart along with a placebo IVIg infusion for 24 weeks, followed by an open-label extension phase with riliprubart for another 24 weeks the other group continues IVIg treatment with a placebo riliprubart for 24 weeks, then also enters the open-label riliprubart extension. Treatments are given as intravenous or subcutaneous infusions, and dosing follows established maintenance regimens. During the study, participants will have regular assessments to monitor their response to treatment. These include measuring disability and fatigue scales, grip strength, and relapse rates from baseline through various time points up to week 109. Safety is monitored by tracking treatment-emergent adverse events and antibody development. Participants are followed closely through scheduled visits to evaluate changes in their condition and overall health status throughout the study.
Actively Recruiting
Researchers are evaluating the effects of therapeutic-dose heparin compared to usual care pharmacological thromboprophylaxis in patients hospitalized with community-acquired pneumonia CAP. The study focuses on the high incidence of hospitalizations due to CAP, which often leads to serious complications including thrombotic events that affect respiratory, cardiac, and other organs. This trial aims to explore whether therapeutic-dose heparin can improve outcomes by targeting inflammatory and thrombotic pathways, a strategy shown to help in COVID-19 but not yet studied in non-COVID-19 CAP. Participants are randomly assigned to one of two groups. One group receives therapeutic-dose low molecular-weight heparin LMWH or unfractionated heparin UFH daily for up to 14 days or until hospital discharge, whichever comes first. The other group receives the usual care thromboprophylaxis dose according to local practice, which is lower than the therapeutic dose. Treatments start as soon as possible after randomization. LMWH is preferred unless contraindicated, with dosing based on patient weight, while UFH may be used in cases of renal impairment. During the study, participants will be monitored for outcomes including survival at 30 days, bleeding events, thrombotic events, mechanical ventilation use, mortality at various timepoints, hospital-free days, and health-related quality of life. The study collects data up to 180 days after treatment. Safety monitoring includes tracking adverse events like bleeding and heparin-induced thrombocytopenia. Participation involves hospital stays expected to last at least 72 hours from randomization, with assessments throughout the treatment period and follow-up extending to 180 days.
Actively Recruiting
Researchers are studying biperiden as a potential preventive treatment for post traumatic epilepsy PTE, a common neurological complication after moderate or severe traumatic brain injury TBI. This research aims to evaluate if biperiden can reduce the occurrence of PTE, assess its side effects, and analyze its cost-effectiveness. The trial focuses on adult patients with moderate or severe TBI, as PTE often develops within two years after injury and currently lacks effective prevention. Participants are randomly assigned to receive either 5 mg of biperiden intravenously every 6 hours for 10 days or a placebo with similar administration. The treatment starts within 18 hours of brain injury. The study includes a two-year follow-up period with regular visits to monitor for epileptic seizures and other outcomes. The trial also examines brain activity through electroencephalogram analyses, genetic markers, and various neuropsychological functions. During the study, participants will undergo multiple assessments including EEG tests at set intervals, neuropsychological evaluations at 6 and 24 months, and quality of life questionnaires. Researchers will track seizure development, side effects of biperiden, and health status over two years. This long-term monitoring helps determine the drugs safety and effects on epilepsy prevention after brain injury.
Actively Recruiting
Researchers are studying neuroendocrine carcinomas NEC, including both pulmonary and extra-pulmonary types, in Latin America to better understand patient treatment patterns and outcomes. This observational, retrospective study aims to fill gaps in knowledge about NEC in Brazil, Mexico, Argentina, and Peru by analyzing medical records. The study is non-interventional, meaning patients receive their usual care while data is collected for research purposes. The study collects detailed information from patient medical records, including demographics, diagnosis methods, tumor characteristics, treatments received such as surgery, chemotherapy, and radiotherapy, and disease progression. Data covers patients diagnosed between August 2014 and August 2024. No experimental treatments are given, and patient care follows standard clinical practice at each site. Participants data is gathered through an electronic system without requiring additional study visits, except for consent if needed. Researchers will evaluate treatment patterns, survival outcomes like event-free survival and progression-free survival, and the expression of the DLL-3 marker over an average follow-up of 24 months. The study will help improve understanding of NEC management and outcomes in the region.
Actively Recruiting
Researchers are conducting a phase III, randomized, multi-center clinical trial to evaluate whether intravenous Tenecteplase TNK treatment is better than a placebo for patients who have suffered a non-large vessel occlusion ischemic stroke between 4.5 and 12 hours after they were last seen well. The study focuses on patients with evidence of salvageable brain tissue or a clinical-radiological mismatch on perfusion imaging. The goal is to determine if TNK can improve functional outcomes compared to placebo. Participants will be randomly assigned in a 11 ratio to receive either a single intravenous bolus injection of Tenecteplase at a dose of 0.25 mgkg maximum 25 mg or a placebo bolus injection over 5 seconds. The study uses a double-blind design, and randomization considers factors such as age, stroke severity, and timing since last seen well. The planned enrollment is 466 participants, split evenly between the TNK and placebo groups, with interim analyses to assess study progress. During the 90-day follow-up, participants will undergo assessments including modified Rankin Scale scoring to evaluate functional outcomes, brain imaging to measure infarct volume and reperfusion, and quality of life questionnaires at 3 months, 6 months, and one year. Safety outcomes like intracranial hemorrhage and mortality rates will also be monitored. These evaluations aim to measure the effectiveness and safety of TNK treatment compared to placebo after ischemic stroke.
Actively Recruiting
Researchers are evaluating the efficacy of perioperative dostarlimab compared with the standard of care in participants with untreated T4N0 or Stage III resectable colon cancer that shows defective mismatch repair or high microsatellite instability dMMRMSI-H. This phase 3, open-label, randomized study focuses on these specific colon cancer patients to assess if dostarlimab can improve outcomes compared to current treatments. Participants are randomly assigned to receive either dostarlimab before and after surgery or the standard of care treatments, which include FOLFOX or CAPEOX chemotherapy or post-surgery observation. Dostarlimab is given as monotherapy during the perioperative period. The study carefully monitors participants for up to approximately 5 years to evaluate long-term effects. During the trial, participants undergo regular assessments including event-free survival reviewed by blinded independent central review, overall survival, and pathological response evaluations. Safety is closely monitored by tracking adverse events, immune-related effects, and serum concentrations of dostarlimab across treatment cycles. The study involves frequent follow-ups to understand treatment impact and ensure participant well-being throughout the extended observation period.
Actively Recruiting
Researchers are conducting a prospective, observational multicenter study to understand severe and very severe COPD in Brazil. This study focuses on patients diagnosed by the GOLD 2024 criteria, considering that COPD severity is linked to exacerbation rates, disease progression, complications, and mortality. It aims to gather data from multiple regions of Brazil, each with different environmental exposures and population characteristics, to fill the gap in national information about this subgroup. Participants will be enrolled consecutively across eight hospitals representing Brazils five regions. The study involves no experimental treatment instead, it observes patients over 12 months with on-site visits at the start, 6 months, and 12 months, plus tele-consultations at 3 and 9 months. Data collected will focus on exacerbations, hospitalizations, mortality, and vaccination status, among other clinical details. Participants will undergo clinical assessments during visits and tele-consults, with data managed and reviewed by the study team. Researchers will measure outcomes such as hospitalizations, exacerbations, mortality, vaccination rates, and lung cancer incidence over approximately one year. The study is observational, so patient care continues as usual, and participant involvement lasts about 12 months.
1-10 of 12
1